A-101 40%

Aclaris Therapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	A-101 40%
Sponsor	Aclaris Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

A-101 40% CI brief — competitive landscape report
A-101 40% updates RSS · CI watch RSS
Aclaris Therapeutics, Inc. portfolio CI